You are viewing the site in preview mode

Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Fig. 3

Serum biomarkers: free RANKL (sRANKL), Osteoprotegerin (OPG), Tartrate-resistant acid phosphatase 5b (TRACP-5b) and Calcium. Levels of sRANKL, OPG, TRACP-5b, detected by ELISA, and Calcium in serum from patients collected at the time of biopsy (Serum A) and surgery (Serum B) in the control and experimental arms. p value T test for comparison between experimental and treatment arm is shown in the upper left corner and p value T test for paired samples is shown for each treatment group. N indicates the number of samples analyzed. Note that Denosumab was associated with reduction in the levels of free RANKL and serum calcium, OPG shows a tendency to increase, while the levels of Trap5b did not change

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us